CG Oncology (CGON) Consolidates After +3% Monthly Gain as Clinical Profile Strengthens
Key Takeaways
- CG Oncology (CGON) is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer.
- The stock has traded in a relatively contained range over the past 30 days, with a modest gain of approximately 3%, reflecting a period of consolidation following stronger year-to-date gains.
- Positive Phase 2 CORE-008 Cohort CX data presented in May demonstrated 96% high-grade event-free survival at three months and 92.3% complete response rates in the efficacy evaluable population, reinforcing the clinical profile of cretostimogene.
- Management expects to complete the company's first Biologics License Application (BLA) submission in the fourth quarter of 2026, targeting high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
- Wall Street maintains a broadly positive stance with a consensus "Strong Buy" rating and an average analyst price target of approximately $90, representing significant upside from recent trading levels.
CGON's Recent Price Action
From what I see, CGON shares have shown relative stability over the past 30 days, advancing roughly 3% as the stock consolidated near the upper end of its recent trading range. The shares closed at $71.40 on August 4, 2026, up from approximately $69.26 a month earlier. This measured pace follows a stronger quarter in which the stock gained about 12%, supported by positive clinical updates, analyst upgrades, and clearer regulatory signals for cretostimogene. With a market capitalization near $6.3 billion, CGON trades above its 50-day and 200-day moving averages, though it remains below the 52-week high of $77.00. Institutional ownership sits at approximately 26.6%, while short interest above 12 days points to a meaningful bearish position that could add volatility around future catalysts. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge the broader momentum signals.
CG Oncology's Business Focus and Competitive Standing
CG Oncology is a late-stage clinical biopharmaceutical company based in Dallas, Texas, focused on developing and commercializing bladder-sparing treatments for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy that selectively replicates in and destroys bladder cancer cells while triggering a systemic anti-tumor immune response. The development program includes two Phase 3 trials—BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC—plus the multi-cohort Phase 2 CORE-008 study. With more than 600 patients treated, a $1.1 billion cash position that funds operations through 2029, and a first-mover position in a market with clear unmet need, CG Oncology stands out in the uro-oncology space.
Recent Developments Shaping Sentiment
Several updates have influenced views on CGON in recent weeks. On May 8, 2026, the company reported first-quarter results, showing a net loss of $0.71 per share—wider than the $0.58 consensus estimate—while revenue of $1.08 million beat expectations. Management also reaffirmed that the first BLA submission is on track for completion in the fourth quarter of 2026 after productive FDA discussions.
One week later, on May 15, positive initial data from the Phase 2 CORE-008 Cohort CX trial were presented at the American Urological Association Annual Meeting. The combination of cretostimogene with gemcitabine achieved a 96.0% high-grade event-free survival rate at three months and 89.5% at six months, with complete response rates of 92.3% in the efficacy evaluable CIS-containing population. No Grade 3 or higher treatment-related adverse events occurred. The results led to reaffirmations from Truist, UBS, Wedbush, RBC Capital, and H.C. Wainwright, all maintaining Buy-equivalent ratings and lifting price targets.
On the corporate side, Jim DeTore joined as Chief Financial Officer in April. Institutional activity has been mixed, with Wellington Management, T. Rowe Price, and State Street adding to positions, while some insider sales by directors James Mulay and Leonard Post drew notice. The elevated short interest continues to reflect divided opinions on the near-term path.
Key Catalysts and Risks for the Rest of 2026
The balance of 2026 should bring several important events for CG Oncology. Topline data from the Phase 3 PIVOT-006 trial in intermediate-risk NMIBC are expected in the first half of the year and could be particularly meaningful given the larger patient population. Durability data from the BOND-003 cohorts and CORE-008 Cohort A are also anticipated later in the year. Completion of the first BLA submission in the fourth quarter represents the most significant regulatory step yet for the pre-commercial company. Investors will want to watch the Q2 2026 earnings report, expected in early August, for further updates on BLA progress, PIVOT-006 timing, and cash runway. Potential risks include clinical or regulatory setbacks, competitive developments, and the possibility that high short interest could magnify price swings around major readouts.
Using AI Tools to Monitor Biotech Names Like CGON
When tracking clinical-stage companies such as CGON, I find it useful to review automated strategies alongside fundamental analysis. Tickeron’s AI Trading Bots provide a practical way to observe how different algorithmic approaches have performed on similar stocks, helping put price action and upcoming catalysts into broader context without replacing core due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CGON sees its Stochastic Oscillator ascends from oversold territory
On July 27, 2026, the Stochastic Oscillator for CGON moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 23 instances where the indicator left the oversold zone. In of the 23 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in of 128 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 94 cases where CGON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CGON moved out of overbought territory on July 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGON as a result. In of 43 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CGON turned negative on July 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 26 similar instances when the indicator turned negative. In of the 26 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.760) is normal, around the industry mean (20.076). P/E Ratio (0.000) is within average values for comparable stocks, (25.135). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.546). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (412.299).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement